Medical News / From ASH Meeting 2020: Anticoagulant, Antiplatelet Use Not Linked to Better COVID-19 Outcomes

Despite significant prevalence of coagulopathy risk in patients with coronavirus 2019 (COVID-19), anticoagulant or antiplatelet therapy may not reduce patients’ risk of severe outcomes. In a new retrospective cohort assessment of patients with COVID-19 treated at Kaiser Permanente Northern California (KPNC) during the early months of the pandemic, investigators observed that neither antiplatelet nor anticoagulant therapy was associated with adjusted reduction of outcomes including venous thromboembolism (VTE). Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

MORE MEDICAL NEWS
ASH Meeting 2020, Novel Educational Programs Can Benefit and Engage Sickle Cell Patients
Children with chronic medical conditions like sickle cell disease may spend a significant amount of time ... read more
From ASH Meeting 2020, Sickle Cell Neurocognitive Screening Measures May Have Inherent Educational Bias
Findings from a new study suggest there may be inherent educational biases in neurocognitive screening measures ... read more
ASH Meeting 2020, Largest Hemophilia B Gene Therapy Study to Date Hits Early Benefit, Safety Marks
The first reported phase 3 trial data for hemophilia B treated with a gene therapy show ... read more
From ASH Meeting 2020, Cerebral Arteriopathy Risk More Common in Sickle Cell Anemic Children
Children with sickle cell anemia face an increased risk of intracranial and extracranial arteriopathy from as ... read more